CDX
OVCAR-3
Tumor indication
Ovarian
Tumor subtype
Ovary adenocarcinoma
Description
OVCAR-3 (Ovarian Cancer CDX Model)
The OVCAR-3 ovarian cancer cell line was derived from ascites of a patient with advanced ovarian adenocarcinoma. It is resistant to adriamycin and platinum-based chemotherapies. OVCAR-3 is widely used in drug discovery focused on resistant ovarian cancer. Its reproducibility supports translational oncology pipelines.
Key Features:
- Derived from advanced ovarian adenocarcinoma.
- Resistant to adriamycin and platinum drugs.
- Epithelial morphology.
- Tumorigenic in xenograft systems.
Applications:
OVCAR-3 supports studies of resistance mechanisms in ovarian cancer. Researchers apply it in biomarker development and drug discovery programs. It is useful for testing novel therapeutics targeting chemotherapy-resistant disease. Its stable performance ensures reliability in translational research.
Details
- Tumor indication
- Ovarian
- Tumor subtype
- Ovary adenocarcinoma
- Organism
- Human
- Mouse sex
- Female
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.